MCID: CLR109
MIFTS: 50

Colorectal Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Colorectal Adenocarcinoma

MalaCards integrated aliases for Colorectal Adenocarcinoma:

Name: Colorectal Adenocarcinoma 12 15 17
Adenocarcinoma of Large Intestine 70

Classifications:



External Ids:

Disease Ontology 12 DOID:0050861
NCIt 50 C5105
SNOMED-CT 67 408645001
UMLS 70 C1319315

Summaries for Colorectal Adenocarcinoma

Disease Ontology : 12 A colorectal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colorectal Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to colorectal adenoma and adenocarcinoma. An important gene associated with Colorectal Adenocarcinoma is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are ERK Signaling and Developmental Biology. The drugs Iron and Hematinics have been mentioned in the context of this disorder. Affiliated tissues include colon, breast and liver, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Colorectal Adenocarcinoma

Diseases related to Colorectal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 583)
# Related Disease Score Top Affiliating Genes
1 colorectal adenoma 32.0 TP53 MSH2 MLH1 KRAS HRAS CTNNB1
2 adenocarcinoma 31.5 TP53 MSH2 MLH1 KRT7 KRT20 KRAS
3 adenoma 31.2 TP53 MSH2 MLH1 KRT7 KRT20 KRAS
4 appendix adenocarcinoma 31.1 KRT7 KRT20 KRAS HRAS CDX2
5 rectum cancer 31.0 MSH2 MLH1 KRT20 KRAS HRAS CEACAM5
6 colon adenocarcinoma 30.9 TP53 MLH1 KRT20 KRAS ERBB2 EGFR
7 mucinous adenocarcinoma 30.9 TP53 MLH1 KRT7 KRT20 KRAS ERBB2
8 bladder adenocarcinoma 30.9 KRT7 KRT20 ERBB2 CDX2
9 gastrointestinal stromal tumor 30.8 TP53 KRAS ERBB2 EGFR CDH1 BRAF
10 lynch syndrome 30.8 TP53 MSH2 MLH1 KRAS HRAS EGFR
11 familial adenomatous polyposis 30.7 TP53 MSH2 MLH1 KRAS HRAS CTNNB1
12 exanthem 30.6 KRAS HRAS ERBB2 EGFR
13 urachal adenocarcinoma 30.5 KRAS CEACAM5 BRAF
14 cystitis cystica 30.5 KRT7 KRT20 CDX2
15 mucinous bronchioloalveolar adenocarcinoma 30.5 KRT7 KRT20 CDX2
16 cystitis 30.4 TP53 KRT7 KRT20 CDH1
17 benign mesothelioma 30.4 KRT7 KRT20 CEACAM5
18 intestinal obstruction 30.4 KRT7 KRT20 CEACAM5 CDX2
19 neuroendocrine carcinoma 30.4 KRT7 KRT20 CEACAM5 CDH1
20 anal fistula 30.4 MSH2 MLH1 KRT7
21 chordoma 30.4 TP53 KRT7 EGFR CDH1
22 rectum adenocarcinoma 30.4 TP53 MSH2 MLH1 KRT7 KRT20 KRAS
23 muir-torre syndrome 30.3 TP53 MSH2 MLH1 KRT7
24 villous adenoma 30.3 TP53 MLH1 KRT7 KRT20 KRAS HRAS
25 sebaceous adenocarcinoma 30.3 TP53 MSH2 MLH1 ERBB2
26 colon adenoma 30.3 MIR182 KRAS CTNNB1
27 mesothelioma, malignant 30.3 KRT7 KRT20 CTNNB1 CEACAM5 CDH1
28 tubular adenocarcinoma 30.3 KRT7 KRT20 ERBB2 EGFR CTNNB1 CEACAM5
29 familial colorectal cancer 30.3 TP53 MSH2 MLH1 CDH1 BRAF
30 embryonal rhabdomyosarcoma 30.2 TP53 KRAS HRAS
31 intrahepatic cholangiocarcinoma 30.2 TP53 KRT7 KRT20 KRAS ERBB2 EGFR
32 gastric adenocarcinoma 30.2 TP53 MLH1 KRT20 KRAS HRAS ERBB2
33 breast ductal carcinoma 30.2 TP53 KRT7 ERBB2 EGFR CTNNB1 CDH1
34 pancreatic ductal adenocarcinoma 30.2 TP53 KRAS ERBB2 EGFR CTNNB1 CDH1
35 pleomorphic adenoma 30.1 TP53 KRT7 HRAS ERBB2 CTNNB1
36 cystadenocarcinoma 30.1 TP53 KRT7 HRAS ERBB2 CEACAM5 BRAF
37 small intestine adenocarcinoma 30.1 MSH2 MLH1 KRAS HRAS CTNNB1
38 renal cell carcinoma, nonpapillary 30.1 TP53 MIR182 KRT7 KRT20 HRAS EGFR
39 sarcoma 30.1 TP53 MSH2 KRAS HRAS CTNNB1 BRAF
40 cholangiocarcinoma 30.1 TP53 KRT7 KRT20 KRAS ERBB2 EGFR
41 squamous cell carcinoma 30.0 TP53 KRT7 HRAS ERBB2 EGFR CTNNB1
42 neuroblastoma 30.0 TP53 HRAS ERBB2 EGFR CTNNB1 AURKA
43 pancreatic adenocarcinoma 30.0 TP53 KRAS HRAS ERBB2 EGFR CTNNB1
44 oral squamous cell carcinoma 30.0 TP53 MIR182 HRAS EGFR CTNNB1 CDH1
45 bronchiolo-alveolar adenocarcinoma 29.9 KRT7 KRT20 KRAS HRAS EGFR CEACAM5
46 melanoma 29.9 TP53 MIR182 KRAS HRAS ERBB2 EGFR
47 carcinosarcoma 29.9 TP53 KRT7 KRAS HRAS ERBB2 EGFR
48 rhabdomyosarcoma 29.9 TP53 MSH2 MLH1 KRT7 KRAS HRAS
49 signet ring cell adenocarcinoma 29.9 TP53 MSH2 MLH1 KRT7 KRT20 KRAS
50 hepatocellular carcinoma 29.8 TP53 PIM2 MSH2 MIR182 KRT7 KRAS

Graphical network of the top 20 diseases related to Colorectal Adenocarcinoma:



Diseases related to Colorectal Adenocarcinoma

Symptoms & Phenotypes for Colorectal Adenocarcinoma

GenomeRNAi Phenotypes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.43 AURKA BRAF EGFR HRAS KRAS PIM2
2 Decreased viability GR00055-A-2 10.43 AURKA BRAF EGFR HRAS KRAS PIM2
3 Decreased viability GR00055-A-3 10.43 KRAS
4 Decreased viability GR00106-A-0 10.43 KRAS
5 Decreased viability GR00173-A 10.43 CDK8
6 Decreased viability GR00221-A-1 10.43 AURKA CDK8 EGFR CDH1 HRAS KRAS
7 Decreased viability GR00221-A-2 10.43 AURKA CDK8 HRAS KRAS
8 Decreased viability GR00221-A-3 10.43 ERBB2 HRAS
9 Decreased viability GR00221-A-4 10.43 AURKA BRAF CDK8 EGFR ERBB2
10 Decreased viability GR00231-A 10.43 AURKA
11 Decreased viability GR00249-S 10.43 AURKA BRAF
12 Decreased viability GR00301-A 10.43 BRAF CDK8 CDH1 KRAS PIM2 MSH2
13 Decreased viability GR00381-A-1 10.43 BRAF KRAS
14 Decreased viability GR00402-S-2 10.43 AURKA CDH1 PIM2
15 Decreased cell migration GR00055-A-3 9.56 AURKA BRAF EGFR HRAS

MGI Mouse Phenotypes related to Colorectal Adenocarcinoma:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.34 AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
2 cardiovascular system MP:0005385 10.28 AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
3 homeostasis/metabolism MP:0005376 10.28 BRAF CDH1 CDK8 CDX2 CTNNB1 EGFR
4 digestive/alimentary MP:0005381 10.24 BRAF CDH1 CDX2 CTNNB1 EGFR ERBB2
5 endocrine/exocrine gland MP:0005379 10.2 BRAF CDH1 CDK8 CDX2 CTNNB1 EGFR
6 embryo MP:0005380 10.18 AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
7 mortality/aging MP:0010768 10.17 AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
8 craniofacial MP:0005382 10.11 BRAF CDK8 CTNNB1 EGFR ERBB2 HRAS
9 integument MP:0010771 10.1 BRAF CDH1 CTNNB1 EGFR ERBB2 HRAS
10 neoplasm MP:0002006 10.03 AURKA BRAF CDH1 CDX2 CTNNB1 EGFR
11 limbs/digits/tail MP:0005371 10.02 AURKA BRAF CDK8 CDX2 CTNNB1 EGFR
12 no phenotypic analysis MP:0003012 9.7 AURKA CDH1 CTNNB1 EGFR HRAS KRAS
13 normal MP:0002873 9.61 BRAF CDH1 CDX2 CTNNB1 EGFR ERBB2
14 respiratory system MP:0005388 9.23 BRAF CTNNB1 EGFR ERBB2 HRAS KRAS

Drugs & Therapeutics for Colorectal Adenocarcinoma

Drugs for Colorectal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4 7439-89-6 23925 29936
2 Hematinics Phase 4
3 Hepcidins Phase 4
4
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
5
Nicotine Approved Phase 3 54-11-5 942 89594
6
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
7
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
8
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
10
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
11
Chlorotrianisene Investigational, Withdrawn Phase 3 569-57-3 11289
12 Mitogens Phase 3
13 Immunoglobulin G Phase 3
14 Endothelial Growth Factors Phase 3
15 Calciferol Phase 3
16 Immunoglobulins Phase 3
17 Antibodies Phase 3
18 Antibodies, Monoclonal Phase 3
19 Calcium, Dietary Phase 3
20 Immunoglobulins, Intravenous Phase 3
21 Formyltetrahydrofolates Phase 3
22 Tetrahydrofolates Phase 3
23
Calcium Nutraceutical Phase 3 7440-70-2 271
24
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
25
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
26
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
27
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
28
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
29
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
30
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
31
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
32
Trifluridine Approved, Investigational Phase 1, Phase 2 70-00-8 6256
33
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
34
Obinutuzumab Approved, Investigational Phase 1, Phase 2 949142-50-1
35
Metformin Approved Phase 2 657-24-9 14219 4091
36
Gemcitabine Approved Phase 2 95058-81-4 60750
37
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
38
Durvalumab Approved, Investigational Phase 2 1428935-60-7
39
Ipilimumab Approved Phase 2 477202-00-9
40
Trametinib Approved Phase 2 871700-17-3 11707110
41
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
42
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
43
Pembrolizumab Approved Phase 2 1374853-91-4
44
Ceritinib Approved Phase 2 1032900-25-6
45
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
46
Pidilizumab Investigational Phase 2 1036730-42-3
47
Tremelimumab Investigational Phase 2 745013-59-6
48
Quinacrine Investigational Phase 1, Phase 2 83-89-6 237
49 Vaccines Phase 2
50 Albumin-Bound Paclitaxel Phase 2

Interventional clinical trials:

(show top 50) (show all 98)
# Name Status NCT ID Phase Drugs
1 An Open Label Study of Intravenous Iron (FERINJECT) in Colorectal Adenocarcinoma Related Anaemia to Identify Potential Biomarkers of Responsiveness to Intravenous Iron Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
2 A Prospective, Randomized, One-center Study Comparing Hepatic Arterial Infusion Plus Chemotherapy ± Target Therapy and Chemotherapy ± Target Therapy Alone in Patients With Unresectable Colorectal Cancer Liver Metastases Unknown status NCT03125161 Phase 3 HAI;chemotherapy ± target therapy
3 A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma Completed NCT02788279 Phase 3 Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
4 A Randomized, Multicenter Phase III Trial to Assess the Efficacy and Safety of Bevacizumab and Capecitabine as Maintenance Treatment, After Initial Combination Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Adenocarcinoma Completed NCT00623805 Phase 3 Bevacizumab;Capecitabine;Oxaliplatin
5 The Impact of Positron Emission Tomography (PET) Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases: A Prospective, Multicentre Randomized Clinical Trial Completed NCT00265356 Phase 3
6 A Multicenter,Randomized, Double-blind, Placebo-controlled Trial of Famitinib in Patients With Advanced Colorectal Adenocarcinoma Completed NCT02390947 Phase 3 Famitinib;Placebo
7 Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS) Recruiting NCT04094688 Phase 3 Bevacizumab;Oxaliplatin;Leucovorin Calcium;Fluorouracil;Irinotecan Hydrochloride;Irinotecan
8 Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer Recruiting NCT02997228 Phase 3 Atezolizumab;Fluorouracil;Leucovorin;Oxaliplatin
9 TACE Associated With Systemic Chemotherapy Versus Systemic Chemotherapy in Patients Who Failed With First Line Chemotherapy Active, not recruiting NCT03783559 Phase 3 TACE;chemotherapy±target therapy
10 Randomized Phase III Trial of 5-FU Based Maintenance Therapy With or Without Panitumumab in Patients With RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX + Panitumumab Terminated NCT03300609 Phase 3 Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
11 Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma. A Phase 3 Randomised Controlled Trial Withdrawn NCT03708536 Phase 3 S-1;Bevacizumab;Capecitabine
12 A Phase II Trial Evaluating a Modified Regimen of Oxaliplatin and Capecitabine in First-Line Treatment of Metastatic Colorectal Adenocarcinoma Unknown status NCT01552967 Phase 2 Capecitabine
13 A Non Randomized Phase II Trial to Assess Efficacy and Safety of Bevacizumab, Capecitabine and Oxaliplatin as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polychemotherapy Treatment Unknown status NCT01067053 Phase 2 bevacizumab, capecitabine, oxaliplatin
14 Phase II Study Evaluating the Association of Bevacizumab and Chemotherapy of the Type Modified FOLFIRI 3 in Patients With Metastatic Colorectal Adenocarcinoma Unknown status NCT00544011 Phase 2 capecitabine;fluorouracil;irinotecan hydrochloride
15 Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma Unknown status NCT00027833 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
16 Phase 2 Study of Neoadjuvant 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma Completed NCT00168155 Phase 2 perioperative chemotherapy
17 Expanded Cohort of Patients With Refractory Metastatic Colorectal Cancer (MCRC) Treated With Bevacizumab and Everolimus Completed NCT00597506 Phase 2 Bevacizumab;Everolimus
18 Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma . Completed NCT02788006 Phase 2 Regorafenib 160 mg
19 Regorafenib Assessment in Refractory Advanced Colorectal Cancer Completed NCT01929616 Phase 2 regorafenib
20 BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer Completed NCT02292758 Phase 2 Irinotecan
21 A Phase IIa Multicenter Evaluation of The Safety And Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment of Patients With Stage III or IV Colorectal Adenocarcinoma Completed NCT00034190 Phase 2 S-8184 Paclitaxel Injectable Emulsion
22 A Phase II Trial of Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma Completed NCT00165217 Phase 2 Capecitabine;Thalidomide
23 Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma Completed NCT01900717 Phase 2 LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
24 A Phase II Trial of Lapatinib and Capectiabine for Patients With Refractory Advanced Colorectal Adenocarcinoma (LAP109859) Completed NCT00574171 Phase 2 lapatinib;Capecitabine
25 Phase II Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease Completed NCT00890305 Phase 2 CT-011;FOLFOX
26 An Open-Label Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With Treatment-Resistant, Metastatic Pancreatic or Colorectal Adenocarcinoma Completed NCT01053013 Phase 2
27 Evaluation of Bevacizumab Combined With First Line Chemotherapy in Patients Aged 75 and Over Suffering From Metastatic Colorectal Adenocarcinoma. Phase II Randomized - Intergroup Trial: FFCD, FNCLCC, GERICO Completed NCT01417494 Phase 2 Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
28 A Single Arm, Multicenter Phase II Study of Everolimus in Patients With Metastatic Colorectal Adenocarcinoma Whose Cancer Has Progressed Despite Prior Therapy With an Anti-EGFR Antibody (if Appropriate), Bevacizumab, Fluoropyrimidine, Oxaliplatin, and Irinotecan-based Regimens Completed NCT00419159 Phase 2 Everolimus (RAD001)
29 A Randomized Phase II Trial of Two Dose Levels of ZD1839 (Iressa) (NSC 715055, IND 61187) in Patients With Recurrent Colorectal Adenocarcinoma Completed NCT00025350 Phase 2 gefitinib
30 Phase II, Open Label, Single Center, Two Arm Study Study to Assess the Safety, Tolerance and Efficacy of a 2 mg Dose of G17DT Via Intramuscular Injection in Patients With Advanced Metastatic Colorectal Adenocarcinoma. Completed NCT02181465 Phase 2
31 A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver Completed NCT00149396 Phase 1, Phase 2 NV1020
32 Phase II Trial Assessing the Impact on the Activity of Daily Living of an Oral Chemotherapy by Capecitabine Associated With an Intravenous Chemotherapy by Oxaliplatin as First Line Treatment of Metastatic Colorectal Adenocarcinoma of Patients Aged Over 70 Completed NCT00104689 Phase 2 capecitabine;oxaliplatin
33 Phase II Study of Abraxane in CIMP-High Colorectal Adenocarcinomas and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
34 A Phase 1/2 Study With Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Recruiting NCT04474470 Phase 1, Phase 2 NT219;NT219 and ERBITUX® - Dose Escalation;NT219 and ERBITUX® - Expansion
35 A Phase II Study of Temozolomide, Cisplatin and Nivolumab in MMR-Proficient Colorectal Cancer Recruiting NCT04457284 Phase 2 Temozolomide (TMZ);Cisplatin;Nivolumab
36 The Role of Multimodality Management in Risk-Stratified Patients With Lung-Limited Metastatic Colorectal Cancer Recruiting NCT03599752 Phase 2 Chemotherapy
37 A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers Recruiting NCT03368963 Phase 1, Phase 2 Nanoliposomal Irinotecan;Trifluridine and Tipiracil Hydrochloride
38 MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer Recruiting NCT03043313 Phase 2 Trastuzumab;Tucatinib
39 Phase A Phase 2 Study Evaluating Response and Biomarkers in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Treated With Nivolumab in Combination With Relatlimab Recruiting NCT03642067 Phase 2 Nivolumab;Relatlimab;Nivolumab;Relatlimab
40 Evaluation of the Effect of the Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Metastatic Colorectal Adenocarcinoma. Phase II Recruiting NCT03559543 Phase 2
41 A Phase II Study Evaluating FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation Recruiting NCT03584711 Phase 2
42 An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290, A Fibroblast Activation Protein-A (FAP) Targeted 4-1BB Ligand (CD137L), In Combination With Cibisatamab With Obinutuzumab Pre-Treatment, In Participants With Previously Treated, Metastatic, Microsatellite-stable Colorectal Adenocarcinoma With High CEACAM5 Expression Recruiting NCT04826003 Phase 1, Phase 2 RO7122290;Cibisatamab;Obinutuzumab
43 A Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Tyrosine Kinase Inhibitor (TKI) in Combination With Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. Recruiting NCT04483219 Phase 2 TKI ± anti-PD-1 antibody
44 Stereotactic Body Radiation Therapy for the Treatment of Unresectable Liver Metastases in Patients With Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors Recruiting NCT02185443 Phase 2
45 Study of Pembrolizumab Combined With Ataluren In Patients With Metastatic pMMR and dMMR Colorectal Adenocarcinomas or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study Recruiting NCT04014530 Phase 1, Phase 2 Ataluren + Pembrolizumab
46 Regorafenib in Adults 70 Years or Older With Metastatic Colorectal Cancer: A Phase II Study Active, not recruiting NCT02466009 Phase 2 Regorafenib
47 Phase II Trial of Nivolumab and Metformin in Patients With Treatment Refractory MSS Metastatic Colorectal Cancer Active, not recruiting NCT03800602 Phase 2 Metformin
48 A Multi-institutional Open Label, Trial Evaluating the Efficacy of Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma With Methylated CHFR and/or Microsatellite Instability Phenotype Active, not recruiting NCT01639131 Phase 2 Gemcitabine;Docetaxel;Filgrastim or Pegfilgrastim
49 Phase II Study of Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma Active, not recruiting NCT02023333 Phase 2 Regorafenib
50 A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies Active, not recruiting NCT02870920 Phase 2 Tremelimumab;Durvalumab

Search NIH Clinical Center for Colorectal Adenocarcinoma

Genetic Tests for Colorectal Adenocarcinoma

Anatomical Context for Colorectal Adenocarcinoma

MalaCards organs/tissues related to Colorectal Adenocarcinoma:

40
Colon, Breast, Liver, Lung, Thyroid, Skin, Lymph Node

Publications for Colorectal Adenocarcinoma

Articles related to Colorectal Adenocarcinoma:

(show top 50) (show all 3746)
# Title Authors PMID Year
1
Pseudomonas aeruginosa recombinant L-asparaginase: Large scale production, purification, and cytotoxicity on THP-1, MDA-MB-231, A549, Caco2 and HCT-116 cell lines. 61
33440252 2021
2
A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. 61
33811727 2021
3
Correction to: Major driver mutations are shared between sinonasal intestinal-type adenocarcinoma and the morphologically identical colorectal adenocarcinoma. 61
33289869 2021
4
Major driver mutations are shared between sinonasal intestinal-type adenocarcinoma and the morphologically identical colorectal adenocarcinoma. 61
33051725 2021
5
[Retracted] LINC01638 silencing inhibits cancer cell proliferation in colorectal adenocarcinoma through interaction with RUNX2. 61
33537797 2021
6
Expression level of long non-coding RNA colon adenocarcinoma hypermethylated serve as a novel prognostic biomarker in patients with thyroid carcinoma. 61
33792624 2021
7
Colorectal adenocarcinomas diagnosed following a negative faecal immunochemical test show high-risk pathological features in a colon screening programme. 61
33037645 2021
8
COVID-19 and the Emergency Presentation of Colorectal Cancer. 61
33793063 2021
9
Tumor microenvironment-associated gene C3 can predict the prognosis of colorectal adenocarcinoma: a study based on TCGA. 61
33765255 2021
10
Screening of immunosuppressive cells from colorectal adenocarcinoma and identification of prognostic markers. 61
33646276 2021
11
DNA damage and DNA protection from digested raw and griddled green pepper (poly)phenols in human colorectal adenocarcinoma cells (HT-29). 61
32430553 2021
12
Immunohistochemical Assessment of Transthyretin Association with Colorectal Adenocarcinoma. 61
33739034 2021
13
IJV thrombophlebitis: be wary of the occult. 61
33731404 2021
14
Characterization of the regulatory 5'-flanking region of bovine mucin 2 (MUC2) gene. 61
33730299 2021
15
In vitro Antioxidant and Cytotoxic Activities of Extracts of Endemic Tanacetum erzincanense Together with Phenolic Content by LC-ESI-QTOF-MS. 61
33464702 2021
16
A 3D physio-mimetic interpenetrating network-based platform to decode the pro and anti-tumorigenic properties of cancer-associated fibroblasts. 61
33766799 2021
17
Combined Inhibition of p38MAPK and PIKfyve Synergistically Disrupts Autophagy to Selectively Target Cancer Cells. 61
33685990 2021
18
The bioactivity of colostrum and milk exosomes of high, average, and low immune responder cows on human intestinal epithelial cells. 61
33358817 2021
19
RAPTA-Decorated Polyacrylamide Nanoparticles: Exploring their Synthesis, Physical Properties and Effect on Cell Viability. 61
33095468 2021
20
Theobromacacao Criollo var. Beans: Biological Properties and Chemical Profile. 61
33803449 2021
21
Structure-Activity Relationship Studies of Acetazolamide-Based Carbonic Anhydrase Inhibitors with Activity against Neisseria gonorrhoeae. 61
33765392 2021
22
The Interaction of the Flavonoid Fisetin with Human Glutathione Transferase A1-1. 61
33806779 2021
23
Synthesis and Biological Evaluation of 1,3,5-Trisubstituted 2-Pyrazolines as Novel Cyclooxygenase-2 Inhibitors with Antiproliferative Activity. 61
33620122 2021
24
Cytoplasmic ADP-ribosylation levels correlate with markers of patient outcome in distinct human cancers. 61
33742140 2021
25
Effect of ethnicity and rurality on treatment delays in patients with colorectal cancer in Northland, New Zealand. 61
32869410 2021
26
Resistance to Cell Death in Mucinous Colorectal Cancer-A Review. 61
33808549 2021
27
Stiffness-tuneable nanocarriers for controlled delivery of ASC-J9 into colorectal cancer cells. 61
33774407 2021
28
L-Glutaminase Synthesis by Marine Halomonas meridiana Isolated from the Red Sea and Its Efficiency against Colorectal Cancer Cell Lines. 61
33807313 2021
29
Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse. 61
33763292 2021
30
A case report of multiple bilateral breast metastases after colorectal cancer. 61
33743246 2021
31
Oral and Intravenous Iron Therapy Differentially Alter the On- and Off-Tumor Microbiota in Anemic Colorectal Cancer Patients. 61
33809624 2021
32
Signet ring cell carcinoma of rectum metastasizing to synchronous renal cell carcinoma: a case report. 61
33731191 2021
33
Mycosis fungoides (CTCL) associated with colorectal adenocarcinoma. A rare case of combined response to neoadjuvant therapy. 61
33798118 2021
34
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. 61
33570712 2021
35
Editorial for the Special Issue "Molecular Biomarkers in Colorectal Adenocarcinoma". 61
33669582 2021
36
Early Onset Colorectal Adenocarcinoma in a 15-Year-Old with Pathogenic Germline Mutations in APC and MLH1: A Case Report. 61
33745841 2021
37
Infiltration of plasma cells in colorectal adenocarcinoma associated with autoimmune encephalitis. 61
33400852 2021
38
Most colitis associated carcinomas lack expression of LGR5: a preliminary study with implications for unique pathways of carcinogenesis compared to sporadic colorectal carcinoma. 61
33541282 2021
39
Histopathology of IBD Colitis. A practical approach from the pathologists of the Italian Group for the study of the gastrointestinal tract (GIPAD). 61
33686309 2021
40
A rare case of metachronous neuroendocrine tumor after a colorectal adenocarcinoma: qualitative critical review of synchronous and metachronous gastrointestinal NET. 61
33044637 2021
41
The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo. 61
33670655 2021
42
Hepatocellular-Targeted mRNA Delivery Using Functionalized Selenium Nanoparticles In Vitro. 61
33668320 2021
43
Oligosaccharides increase the genotoxic effect of colibactin produced by pks+ Escherichia coli strains. 61
33596864 2021
44
A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection. 61
33637768 2021
45
A comparative analysis of outcomes of open, laparoscopic, and robotic elective (procto-) colectomies for benign and malignant disease. 61
32297148 2021
46
Mitochondria specific highly cytoselective iridium(iii)-Cp* dipyridophenazine (dppz) complexes as cancer cell imaging agents. 61
33507192 2021
47
Metastatic colorectal micropapillary carcinoma presenting as lymphangitic lung carcinomatosis. 61
33040282 2021
48
Specific Lactobacillus probiotic strains decrease transepithelial glucose transport through GLUT2 downregulation in intestinal epithelial cell models. 61
33450655 2021
49
Antiviral Activity of Vacuolar ATPase Blocker Diphyllin against SARS-CoV-2. 61
33668694 2021
50
Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy. 61
33317839 2021

Variations for Colorectal Adenocarcinoma

Expression for Colorectal Adenocarcinoma

Search GEO for disease gene expression data for Colorectal Adenocarcinoma.

Pathways for Colorectal Adenocarcinoma

Pathways related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 TP53 KRAS HRAS ERBB2 EGFR CTNNB1
2
Show member pathways
13.53 KRT7 KRT20 KRAS HRAS ERBB2 EGFR
3
Show member pathways
13.33 KRAS HRAS ERBB2 EGFR CTNNB1 CDH1
4
Show member pathways
13.04 TP53 KRAS HRAS ERBB2 EGFR CTNNB1
5
Show member pathways
13.04 TP53 KRAS HRAS CTNNB1 CDH1 BRAF
6
Show member pathways
12.96 KRAS HRAS ERBB2 EGFR CTNNB1 BRAF
7
Show member pathways
12.87 TP53 KRAS HRAS ERBB2 EGFR BRAF
8 12.81 TP53 KRAS HRAS ERBB2 EGFR BRAF
9
Show member pathways
12.78 TP53 KRAS HRAS ERBB2 EGFR
10
Show member pathways
12.78 KRAS HRAS EGFR CTNNB1 CDH1 BRAF
11
Show member pathways
12.76 TP53 MSH2 MLH1 KRAS HRAS ERBB2
12
Show member pathways
12.74 TP53 KRAS HRAS ERBB2 CTNNB1 CDH1
13
Show member pathways
12.73 TP53 MSH2 MLH1 KRAS HRAS
14
Show member pathways
12.72 TP53 KRAS HRAS EGFR BRAF
15
Show member pathways
12.69 TP53 KRAS HRAS ERBB2 EGFR CDH1
16
Show member pathways
12.69 TP53 MLH1 KRAS HRAS ERBB2 EGFR
17
Show member pathways
12.6 TP53 MSH2 KRAS HRAS ERBB2 EGFR
18 12.59 TP53 KRAS HRAS ERBB2 EGFR
19 12.56 TP53 MSH2 MLH1 CDK8 AURKA
20
Show member pathways
12.56 TP53 KRAS HRAS ERBB2 EGFR BRAF
21
Show member pathways
12.54 TP53 KRAS HRAS ERBB2 EGFR BRAF
22
Show member pathways
12.48 TP53 KRAS HRAS ERBB2 EGFR CTNNB1
23
Show member pathways
12.47 EGFR CTNNB1 CDH1 BRAF
24
Show member pathways
12.45 KRAS HRAS CTNNB1 BRAF
25
Show member pathways
12.44 KRAS HRAS ERBB2 EGFR CTNNB1 CDH1
26
Show member pathways
12.38 TP53 KRAS HRAS EGFR CTNNB1 CDH1
27
Show member pathways
12.37 TP53 HRAS ERBB2 EGFR CTNNB1
28
Show member pathways
12.36 KRAS HRAS ERBB2 EGFR
29
Show member pathways
12.36 TP53 KRAS HRAS EGFR BRAF
30
Show member pathways
12.32 KRAS HRAS FGFBP1 BRAF
31 12.31 TP53 KRAS HRAS ERBB2 EGFR CTNNB1
32
Show member pathways
12.3 KRAS HRAS ERBB2 EGFR CTNNB1 CDH1
33
Show member pathways
12.28 TP53 KRAS HRAS ERBB2 EGFR BRAF
34 12.24 KRAS HRAS EGFR CTNNB1 BRAF
35
Show member pathways
12.23 TP53 KRAS HRAS BRAF
36
Show member pathways
12.2 TP53 KRAS HRAS BRAF
37
Show member pathways
12.2 KRAS HRAS ERBB2 EGFR
38 12.2 KRAS HRAS ERBB2 EGFR BRAF AURKA
39 12.15 KRT20 KRAS HRAS EGFR
40
Show member pathways
12.14 TP53 KRAS HRAS EGFR
41
Show member pathways
12.14 KRAS HRAS EGFR BRAF
42 12.12 TP53 MSH2 MLH1 EGFR
43
Show member pathways
12.11 KRAS HRAS ERBB2 EGFR
44 12.09 TP53 PIM2 MSH2 MLH1 KRAS HRAS
45 12.08 TP53 MSH2 MLH1 KRAS EGFR CTNNB1
46 12.07 KRAS HRAS CTNNB1 CDH1
47
Show member pathways
12.07 TP53 ERBB2 EGFR BRAF
48 12.06 TP53 KRAS HRAS CTNNB1
49 12.03 TP53 KRAS HRAS ERBB2 CTNNB1
50
Show member pathways
12.01 KRAS HRAS ERBB2 EGFR

GO Terms for Colorectal Adenocarcinoma

Cellular components related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 basolateral plasma membrane GO:0016323 9.46 ERBB2 EGFR CTNNB1 CEACAM5
2 perinuclear region of cytoplasm GO:0048471 9.1 HRAS ERBB2 EGFR CTNNB1 CDH1 AURKA
3 flotillin complex GO:0016600 8.96 CTNNB1 CDH1

Biological processes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 10.04 TP53 PIM2 EGFR CTNNB1 CDX2 CDH1
2 phosphorylation GO:0016310 10.02 PIM2 ERBB2 EGFR CDK8 BRAF AURKA
3 protein phosphorylation GO:0006468 9.95 PIM2 ERBB2 EGFR CDK8 BRAF AURKA
4 positive regulation of protein phosphorylation GO:0001934 9.88 KRAS HRAS ERBB2 EGFR
5 negative regulation of cell proliferation GO:0008285 9.85 TP53 PIM2 HRAS FGFBP1 FABP6 CTNNB1
6 protein autophosphorylation GO:0046777 9.84 PIM2 ERBB2 EGFR AURKA
7 MAPK cascade GO:0000165 9.83 KRAS HRAS ERBB2 EGFR BRAF
8 Ras protein signal transduction GO:0007265 9.8 TP53 KRAS HRAS
9 cellular response to drug GO:0035690 9.79 TP53 EGFR BRAF
10 cellular response to growth factor stimulus GO:0071363 9.78 ERBB2 EGFR CTNNB1
11 negative regulation of neuron apoptotic process GO:0043524 9.76 MSH2 KRAS HRAS BRAF
12 positive regulation of epithelial cell proliferation GO:0050679 9.75 HRAS ERBB2 EGFR
13 positive regulation of cell proliferation GO:0008284 9.7 KRAS HRAS FGFBP1 ERBB2 EGFR CTNNB1
14 positive regulation of isotype switching to IgG isotypes GO:0048304 9.62 MSH2 MLH1
15 positive regulation of fibroblast growth factor receptor signaling pathway GO:0045743 9.62 FGFBP1 CTNNB1
16 response to isolation stress GO:0035900 9.6 KRAS HRAS
17 entry of bacterium into host cell GO:0035635 9.59 CTNNB1 CDH1
18 negative regulation of ERBB signaling pathway GO:1901185 9.56 ERBB2 EGFR
19 positive regulation of MAP kinase activity GO:0043406 9.56 KRAS HRAS ERBB2 EGFR
20 cellular response to indole-3-methanol GO:0071681 9.52 CTNNB1 CDH1
21 positive regulation of isotype switching to IgA isotypes GO:0048298 9.51 MSH2 MLH1
22 anterior/posterior axis specification GO:0009948 9.5 CTNNB1 CDX2 AURKA
23 negative regulation of apoptotic process GO:0043066 9.5 TP53 PIM2 EGFR CTNNB1 CEACAM5 BRAF
24 somatic recombination of immunoglobulin gene segments GO:0016447 9.49 MSH2 MLH1
25 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.4 MSH2 MLH1
26 positive regulation of gene expression GO:0010628 9.17 TP53 MIR182 KRAS HRAS ERBB2 CTNNB1

Molecular functions related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.88 TP53 MSH2 EGFR CTNNB1 AURKA
2 chromatin binding GO:0003682 9.85 TP53 MSH2 MLH1 EGFR CTNNB1
3 kinase activity GO:0016301 9.85 PIM2 ERBB2 EGFR CDK8 BRAF AURKA
4 enzyme binding GO:0019899 9.8 TP53 MSH2 MLH1 EGFR CTNNB1
5 protein C-terminus binding GO:0008022 9.73 MSH2 HRAS ERBB2 CTNNB1
6 protein kinase activity GO:0004672 9.73 PIM2 ERBB2 EGFR CDK8 BRAF AURKA
7 ATP binding GO:0005524 9.61 TP53 PIM2 MSH2 MLH1 ERBB2 EGFR
8 protein phosphatase binding GO:0019903 9.46 TP53 ERBB2 EGFR CTNNB1
9 guanine/thymine mispair binding GO:0032137 9.32 MSH2 MLH1
10 nucleotide binding GO:0000166 9.32 PIM2 MSH2 MLH1 KRAS HRAS ERBB2

Sources for Colorectal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....